Aligos Therapeutics, Inc. (NASDAQ:ALGS) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) have been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $38.50.

Several research analysts have recently commented on the stock. Lake Street Capital initiated coverage on shares of Aligos Therapeutics in a report on Thursday, May 28th. They set a “buy” rating and a $45.00 target price on the stock. Weiss Ratings upgraded Aligos Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Aligos Therapeutics in a research report on Friday, May 29th. Finally, HC Wainwright reissued a “buy” rating on shares of Aligos Therapeutics in a research report on Monday, August 10th.

Institutional Trading of Aligos Therapeutics

Institutional investors have recently modified their holdings of the stock. Rockefeller Capital Management L.P. lifted its stake in Aligos Therapeutics by 900.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after purchasing an additional 9,000 shares during the last quarter. SummitTX Capital L.P. increased its stake in shares of Aligos Therapeutics by 6.7% in the 1st quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock valued at $1,106,000 after purchasing an additional 9,375 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Aligos Therapeutics by 17.6% in the 1st quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock valued at $746,000 after purchasing an additional 15,006 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Aligos Therapeutics by 1,652.8% during the 1st quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock worth $1,707,000 after buying an additional 216,646 shares in the last quarter. 60.43% of the stock is currently owned by institutional investors.

Aligos Therapeutics Stock Performance

ALGS stock opened at $5.05 on Thursday. The company’s 50-day simple moving average is $5.85 and its 200 day simple moving average is $6.20. Aligos Therapeutics has a 52 week low of $3.98 and a 52 week high of $13.69. The company has a market capitalization of $31.51 million, a PE ratio of -0.69 and a beta of 2.34.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.95. The business had revenue of $27.78 million during the quarter, compared to analysts’ expectations of $24.68 million. Aligos Therapeutics had a negative net margin of 241.01% and a negative return on equity of 160.72%. On average, analysts forecast that Aligos Therapeutics will post -6.81 EPS for the current year.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.